Tubular Epithelial Cell HMGB1 Promotes AKI-CKD Transition by Sensitizing Cycling Tubular Cells to Oxidative Stress: A Rationale for Targeting HMGB1 during AKI Recovery.
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
28
12
2021
accepted:
22
10
2022
pmc-release:
01
03
2024
pubmed:
2
3
2023
medline:
4
3
2023
entrez:
1
3
2023
Statut:
ppublish
Résumé
Cells undergoing necrosis release extracellular high mobility group box (HMGB)-1, which triggers sterile inflammation upon AKI in mice. Neither deletion of HMGB1 from tubular epithelial cells, nor HMGB1 antagonism with small molecules, affects initial ischemic tubular necrosis and immediate GFR loss upon unilateral ischemia/reperfusion injury (IRI). On the contrary, tubular cell-specific HMGB1 deficiency, and even late-onset pharmacological HMGB1 inhibition, increased functional and structural recovery from AKI, indicating that intracellular HMGB1 partially counters the effects of extracellular HMGB1. In vitro studies indicate that intracellular HMGB1 decreases resilience of tubular cells from prolonged ischemic stress, as in unilateral IRI. Intracellular HMGB1 is a potential target to enhance kidney regeneration and to improve long-term prognosis in AKI. Late diagnosis is a hurdle for treatment of AKI, but targeting AKI-CKD transition may improve outcomes. High mobility group box-1 (HMGB1) is a nuclear regulator of transcription and a driver of necroinflammation in AKI. We hypothesized that HMGB1 would also modulate AKI-CKD transition in other ways. We conducted single-cell transcriptome analysis of human and mouse AKI and mouse in vivo and in vitro studies with tubular cell-specific depletion of Hmgb1 and HMGB1 antagonists. HMGB1 was ubiquitously expressed in kidney cells. Preemptive HMGB1 antagonism with glycyrrhizic acid (Gly) and ethyl pyruvate (EP) did not affect postischemic AKI but attenuated AKI-CKD transition in a model of persistent kidney hypoxia. Consistently, tubular Hmgb1 depletion in Pax8 rtTA, TetO Cre, Hmgb1fl/fl mice did not protect from AKI, but from AKI-CKD transition. In vitro studies confirmed that absence of HMGB1 or HMGB1 inhibition with Gly and EP does not affect ischemic necrosis of growth-arrested differentiated tubular cells but increased the resilience of cycling tubular cells that survived the acute injury to oxidative stress. This effect persisted when neutralizing extracellular HMGB1 with 2G7. Consistently, late-onset HMGB1 blockade with EP started after the peak of ischemic AKI in mice prevented AKI-CKD transition, even when 2G7 blocked extracellular HMGB1. Treatment of AKI could become feasible when ( 1 ) focusing on long-term outcomes of AKI; ( 2 ) targeting AKI-CKD transition with drugs initiated after the AKI peak; and ( 3 ) targeting with drugs that block HMGB1 in intracellular and extracellular compartments.
Sections du résumé
SIGNIFICANCE STATEMENT
Cells undergoing necrosis release extracellular high mobility group box (HMGB)-1, which triggers sterile inflammation upon AKI in mice. Neither deletion of HMGB1 from tubular epithelial cells, nor HMGB1 antagonism with small molecules, affects initial ischemic tubular necrosis and immediate GFR loss upon unilateral ischemia/reperfusion injury (IRI). On the contrary, tubular cell-specific HMGB1 deficiency, and even late-onset pharmacological HMGB1 inhibition, increased functional and structural recovery from AKI, indicating that intracellular HMGB1 partially counters the effects of extracellular HMGB1. In vitro studies indicate that intracellular HMGB1 decreases resilience of tubular cells from prolonged ischemic stress, as in unilateral IRI. Intracellular HMGB1 is a potential target to enhance kidney regeneration and to improve long-term prognosis in AKI.
BACKGROUND
Late diagnosis is a hurdle for treatment of AKI, but targeting AKI-CKD transition may improve outcomes. High mobility group box-1 (HMGB1) is a nuclear regulator of transcription and a driver of necroinflammation in AKI. We hypothesized that HMGB1 would also modulate AKI-CKD transition in other ways.
METHODS
We conducted single-cell transcriptome analysis of human and mouse AKI and mouse in vivo and in vitro studies with tubular cell-specific depletion of Hmgb1 and HMGB1 antagonists.
RESULTS
HMGB1 was ubiquitously expressed in kidney cells. Preemptive HMGB1 antagonism with glycyrrhizic acid (Gly) and ethyl pyruvate (EP) did not affect postischemic AKI but attenuated AKI-CKD transition in a model of persistent kidney hypoxia. Consistently, tubular Hmgb1 depletion in Pax8 rtTA, TetO Cre, Hmgb1fl/fl mice did not protect from AKI, but from AKI-CKD transition. In vitro studies confirmed that absence of HMGB1 or HMGB1 inhibition with Gly and EP does not affect ischemic necrosis of growth-arrested differentiated tubular cells but increased the resilience of cycling tubular cells that survived the acute injury to oxidative stress. This effect persisted when neutralizing extracellular HMGB1 with 2G7. Consistently, late-onset HMGB1 blockade with EP started after the peak of ischemic AKI in mice prevented AKI-CKD transition, even when 2G7 blocked extracellular HMGB1.
CONCLUSION
Treatment of AKI could become feasible when ( 1 ) focusing on long-term outcomes of AKI; ( 2 ) targeting AKI-CKD transition with drugs initiated after the AKI peak; and ( 3 ) targeting with drugs that block HMGB1 in intracellular and extracellular compartments.
Identifiants
pubmed: 36857499
doi: 10.1681/ASN.0000000000000024
pii: 00001751-202303000-00009
pmc: PMC10103235
doi:
Substances chimiques
HMGB1 Protein
0
Glycyrrhizic Acid
6FO62043WK
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
394-411Subventions
Organisme : NIDDK NIH HHS
ID : UC2 DK126024
Pays : United States
Informations de copyright
Copyright © 2023 by the American Society of Nephrology.
Références
Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders H-J. Acute kidney injury. Nat Rev Dis Primers. 2021;7(1):52. doi: 10.1038/s41572-021-00284-z
doi: 10.1038/s41572-021-00284-z
Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58-66. doi: 10.1056/nejmra1214243
doi: 10.1056/nejmra1214243
Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK. Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol. 2015;26(8):1765-1776. doi: 10.1681/ASN.2015010006
doi: 10.1681/ASN.2015010006
Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442-448. doi: 10.1038/ki.2011.379
doi: 10.1038/ki.2011.379
Tanaka S, Tanaka T, Nangaku M. Hypoxia as a key player in the AKI-to-CKD transition. Am J Physiol Renal Physiol. 2014;307(11):F1187-F1195. doi: 10.1152/ajprenal.00425.2014
doi: 10.1152/ajprenal.00425.2014
Bábíčková J, Klinkhammer BM, Buhl EM, et al. Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular capillaries. Kidney Int. 2017;91(1):70-85. doi: 10.1016/j.kint.2016.07.038
doi: 10.1016/j.kint.2016.07.038
Ullah MM, Basile DP. Role of renal hypoxia in the progression from acute kidney injury to chronic kidney disease. Semin Nephrol. 2019;39(6):567-580. doi: 10.1016/j.semnephrol.2019.10.006
doi: 10.1016/j.semnephrol.2019.10.006
Mimura I, Nangaku M. The suffocating kidney: Tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol. 2010;6(11):667-678. doi: 10.1038/nrneph.2010.124
doi: 10.1038/nrneph.2010.124
Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta. 2010;1799(1-2):101-113. doi: 10.1016/j.bbagrm.2009.09.008
doi: 10.1016/j.bbagrm.2009.09.008
Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29(1):139-162. doi: 10.1146/annurev-immunol-030409-101323
doi: 10.1146/annurev-immunol-030409-101323
Zhao Z, Hu Z, Zeng R, Yao Y. HMGB1 in kidney diseases. Life Sci. 2020;259:118203. doi: 10.1016/j.lfs.2020.118203
doi: 10.1016/j.lfs.2020.118203
Miura K, Sahara H, Sekijima M, et al. Protective effect of neutralization of the extracellular high-mobility group box 1 on renal ischemia-reperfusion injury in miniature swine. Transplantation. 2014;98(9):937-943. doi: 10.1097/tp.0000000000000358
doi: 10.1097/tp.0000000000000358
Li J, Gong Q, Zhong S, et al. Neutralization of the extracellular HMGB1 released by ischaemic damaged renal cells protects against renal ischaemia-reperfusion injury. Nephrol Dial Transplant. 2011;26(2):469-478. doi: 10.1093/ndt/gfq466
doi: 10.1093/ndt/gfq466
Wu H, Ma J, Wang P, et al. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol. 2010;21(11):1878-1890. doi: 10.1681/ASN.2009101048
doi: 10.1681/ASN.2009101048
Yanai H, Matsuda A, An J, et al. Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. Proc Natl Acad Sci USA. 2013;110(51):20699-20704. doi: 10.1073/pnas.1320808110
doi: 10.1073/pnas.1320808110
Huang H, Nace GW, McDonald K-A, et al. Hepatocyte-specific high-mobility group box 1 deletion worsens the injury in liver ischemia/reperfusion: a role for intracellular high-mobility group box 1 in cellular protection. Hepatology. 2014;59(5):1984-1997. doi: 10.1002/hep.26976
doi: 10.1002/hep.26976
Yu P, Liu M, Zhang B, et al. Cardiomyocyte-restricted high-mobility group box 1 (HMGB1) deletion leads to small heart and glycolipid metabolic disorder through GR/PGC-1α signalling. Cell Death Discov. 2020;6:106. doi: 10.1038/s41420-020-00340-9
doi: 10.1038/s41420-020-00340-9
Kulkarni OP, Hartter I, Mulay SR, et al. Toll-like receptor 4-induced IL-22 accelerates kidney regeneration. J Am Soc Nephrol. 2014;25(5):978-989. doi: 10.1681/ASN.2013050528
doi: 10.1681/ASN.2013050528
Nakazawa D, Kumar SV, Marschner J, et al. Histones and neutrophil extracellular traps enhance tubular necrosis and remote organ injury in ischemic AKI. J Am Soc Nephrol. 2017;28(6):1753-1768. doi: 10.1681/ASN.2016080925
doi: 10.1681/ASN.2016080925
Salei N, Rambichler S, Salvermoser J, et al. The kidney contains ontogenetically distinct dendritic cell and macrophage subtypes throughout development that differ in their inflammatory properties. J Am Soc Nephrol. 2020;31(2):257-278. doi: 10.1681/ASN.2019040419
doi: 10.1681/ASN.2019040419
Marschner JA, Schäfer H, Holderied A, Anders H-J. Optimizing mouse surgery with online rectal temperature monitoring and preoperative heat supply. Effects on post-ischemic acute kidney injury. PLoS One. 2016;11(2):e0149489. doi: 10.1371/journal.pone.0149489
doi: 10.1371/journal.pone.0149489
Schreiber A, Shulhevich Y, Geraci S, et al. Transcutaneous measurement of renal function in conscious mice. Am J Physiology Renal Physiol. 2012;303(5):F783-F788. doi: 10.1152/ajprenal.00279.2012
doi: 10.1152/ajprenal.00279.2012
Lech M, Avila-Ferrufino A, Allam R, et al. Resident dendritic cells prevent postischemic acute renal failure by help of single Ig IL-1 receptor-related protein. J Immunol. 2009;183(6):4109-4118. doi: 10.4049/jimmunol.0900118
doi: 10.4049/jimmunol.0900118
Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671-675. doi: 10.1038/nmeth.2089
doi: 10.1038/nmeth.2089
Mulay SR, Thomasova D, Ryu M, Anders H-J. MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice. Kidney Int. 2012;81(12):1199-1211. doi: 10.1038/ki.2011.482
doi: 10.1038/ki.2011.482
Kirita Y, Wu H, Uchimura K, Wilson PC, Humphreys BD. Cell profiling of mouse acute kidney injury reveals conserved cellular responses to injury. Proc Natl Acad Sci USA. 2020;117(27):15874-15883. doi: 10.1073/pnas.2005477117
doi: 10.1073/pnas.2005477117
Muto Y, Wilson PC, Ledru N, et al. Single cell transcriptional and chromatin accessibility profiling redefine cellular heterogeneity in the adult human kidney. Nat Commun. 2021;12(1):21902021. doi: 10.1038/s41467-021-22368-w
doi: 10.1038/s41467-021-22368-w
Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573-3587.e29. doi: 10.1016/j.cell.2021.04.048
doi: 10.1016/j.cell.2021.04.048
Terryn S, Jouret F, Vandenabeele F, et al. A primary culture of mouse proximal tubular cells, established on collagen-coated membranes. Am J Physiol Renal Physiol. 2007;293(2):F476-F485. doi: 10.1152/ajprenal.00363.2006
doi: 10.1152/ajprenal.00363.2006
Hagemann JH, Thomasova D, Mulay SR, Anders H-J. Nrf2 signalling promotes ex vivo tubular epithelial cell survival and regeneration via murine double minute (MDM)-2. Nephrol Dial Transplant. 2013;28(8):2028-2037. doi: 10.1093/ndt/gft037
doi: 10.1093/ndt/gft037
Lech M, Anders H-J. Expression profiling by real-time quantitative polymerase chain reaction (RT-qPCR). Methods Mol Biol. 2014;1169:133-142. doi: 10.1007/978-1-4939-0882-0_13
doi: 10.1007/978-1-4939-0882-0_13
Fu Y, Tang C, Cai J, Chen G, Zhang D, Dong Z. Rodent models of AKI-CKD transition. Am J Physiology Renal Physiol. 2018;315(4):F1098–F1106. doi: 10.1152/ajprenal.00199.2018
doi: 10.1152/ajprenal.00199.2018
Finn WF. Enhanced recovery from postischemic acute renal failure. Micropuncture studies in the rat. Circ Res. 1980;46(3):440-448. doi: 10.1161/01.res.46.3.440
doi: 10.1161/01.res.46.3.440
Lau A, Wang S, Liu W, Haig A, Zhang Z-X, Jevnikar AM. Glycyrrhizic acid ameliorates HMGB1-mediated cell death and inflammation after renal ischemia reperfusion injury. Am J Nephrol. 2014;40(1):84-95. doi: 10.1159/000364908
doi: 10.1159/000364908
Chung KY, Park JJ, Kim YS. The role of high-mobility group box-1 in renal ischemia and reperfusion injury and the effect of ethyl pyruvate. Transplant Proc. 2008;40(7):2136-2138. doi: 10.1016/j.transproceed.2008.06.040
doi: 10.1016/j.transproceed.2008.06.040
Rabadi MM, Ghaly T, Goligorksy MS, Ratliff BB. HMGB1 in renal ischemic injury. Am J Physiol Renal Physiol. 2012;303(6):F873-F885. doi: 10.1152/ajprenal.00092.2012
doi: 10.1152/ajprenal.00092.2012
Seo MS, Kim HJ, Kim H, Park SW. Ethyl pyruvate directly attenuates active secretion of HMGB1 in proximal tubular cells via induction of heme oxygenase-1. J Clin Med. 2019;8(5):629. doi: 10.3390/jcm8050629
doi: 10.3390/jcm8050629
Sakamoto R, Okano M, Takena H, Ohtsuki K. Inhibitory effect of glycyrrhizin on the phosphorylation and DNA-binding abilities of high mobility group proteins 1 and 2 in vitro. Biol Pharm Bull. 2001;24(8):906-911. doi: 10.1248/bpb.24.906
doi: 10.1248/bpb.24.906
Tang D, Kang R, Livesey KM, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010;190(5):881-892. doi: 10.1083/jcb.200911078
doi: 10.1083/jcb.200911078
Bouchard M, Souabni A, Busslinger M. Tissue-specific expression of cre recombinase from the Pax8 locus. Genesis. 2004;38(3):105-109. doi: 10.1002/gene.20008
doi: 10.1002/gene.20008
Schierbeck H, Lundbäck P, Palmblad K, et al. Monoclonal anti-HMGB1 (high mobility group box chromosomal protein1) antibody protection in two experimental arthritis models. Mol Med. 2011;17(9-10):1039-1044. doi: 10.2119/molmed.2010.00264
doi: 10.2119/molmed.2010.00264
Lundbäck P, Lea JD, Sowinska A, et al. A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice. Hepatology. 2016;64(5):1699-1710. doi: 10.1002/hep.28736
doi: 10.1002/hep.28736
Chang J, Xia Y, Wasserloos K, et al. Cyclic stretch induced IL-33 production through HMGB1/TLR-4 signaling pathway in murine respiratory epithelial cells. PLoS One. 2017;12(9):e0184770. doi: 10.1371/journal.pone.0184770 .
doi: 10.1371/journal.pone.0184770
Lee JD, Liu N, Levin SC, et al. Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2019;16(1):45. doi: 10.1186/s12974-019-1435-2
doi: 10.1186/s12974-019-1435-2
Lazzeri E, Angelotti ML, Peired A, et al. Endocycle-related tubular cell hypertrophy and progenitor proliferation recover renal function after acute kidney injury. Nat Commun. 2018;9(1):1344. doi: 10.1038/s41467-018-03753-4
doi: 10.1038/s41467-018-03753-4
Huebener P, Pradere J-P, Hernandez C, et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest. 2015;125(2):539-550. doi: 10.1172/jci76887
doi: 10.1172/jci76887
Wang Z, Zhou H, Zheng H, et al. Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation. Autophagy. 2021;17(2):529-552. doi: 10.1080/15548627.2020.1725381
doi: 10.1080/15548627.2020.1725381
Mulay SR, Linkermann A, Anders H-J. Necroinflammation in kidney disease. J Am Soc Nephrol. 2016;27(1):27-39. doi: 10.1681/ASN.2015040405
doi: 10.1681/ASN.2015040405
Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S, Dong Z. Regulated cell death in AKI. J Am Soc Nephrol. 2014;25(12):2689-2701. doi: 10.1681/ASN.2014030262
doi: 10.1681/ASN.2014030262
Belavgeni A, Meyer C, Stumpf J, Hugo C, Linkermann A. Ferroptosis and necroptosis in the kidney. Cell Chem Biol. 2020;27(4):448-462. doi: 10.1016/j.chembiol.2020.03.016
doi: 10.1016/j.chembiol.2020.03.016
Tonnus W, Meyer C, Steinebach C, et al. Dysfunction of the key ferroptosis-surveilling systems hypersensitizes mice to tubular necrosis during acute kidney injury. Nat Commun. 2021;12(1):4402. doi: 10.1038/s41467-021-24712-6
doi: 10.1038/s41467-021-24712-6
Anders HJ. Immune system modulation of kidney regeneration—mechanisms and implications. Nat Rev Nephrol. 2014;10(6):347-358. doi: 10.1038/nrneph.2014.68
doi: 10.1038/nrneph.2014.68
Lech M, Gröbmayr R, Ryu M, et al. Macrophage phenotype controls long-term AKI outcomes—kidney regeneration versus atrophy. J Am Soc Nephrol. 2014;25(2):292-304. doi: 10.1681/ASN.2013020152
doi: 10.1681/ASN.2013020152
Man SM, Kanneganti T-D. Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nat Rev Immunol. 2016;16(1):7-21. doi: 10.1038/nri.2015.7
doi: 10.1038/nri.2015.7
Shin J-H, Lee H-K, Lee H-B, Jin Y, Lee J-K. Ethyl pyruvate inhibits HMGB1 phosphorylation and secretion in activated microglia and in the postischemic brain. Neurosci Lett. 2014;558:159-163. doi: 10.1016/j.neulet.2013.11.006
doi: 10.1016/j.neulet.2013.11.006
Davé SH, Tilstra JS, Matsuoka K, et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol. 2009;86(3):633-643. doi: 10.1189/jlb.1008662
doi: 10.1189/jlb.1008662
Peired AJ, Lazzeri E, Guzzi F, Anders H-J, Romagnani P. From kidney injury to kidney cancer. Kidney Int. 2021;100(1):55-66. doi: 10.1016/j.kint.2021.03.011
doi: 10.1016/j.kint.2021.03.011